The concerns over suicide ideation — thinking about or planning suicide — emerged last year when the Icelandic drug agency reported to the EMA two cases in people taking GLP-1s. One was taking Saxenda, Novo Nordisk’s daily weight-loss shot, and the other was taking Ozempic, Novo’s weekly diabetes shot that is often used off-label for obesity. Icelandic authorities also reported one case of self-harm in a person taking Saxenda.
